G
Gabriel Nistor
Researcher at University of California, Irvine
Publications - 59
Citations - 3366
Gabriel Nistor is an academic researcher from University of California, Irvine. The author has contributed to research in topics: Stem cell & Transplantation. The author has an hindex of 19, co-authored 52 publications receiving 3087 citations. Previous affiliations of Gabriel Nistor include University of California.
Papers
More filters
Journal ArticleDOI
In vitro differentiation potential of human embryonic versus adult stem cells.
TL;DR: It is demonstrated that human embryonic stem cells and human neural stem cells have the ability to differentiate into high purity neuronal progenitor or oligodendrocyte progenitors cultures in in vitro cultures.
Journal ArticleDOI
Safety assessment of myogenic stem cell transplantation and resulting tumor formation.
Stephanie A. Jacobs,Felicia Lane,Quynh Anh Pham,Gabriel Nistor,Rockelle Robles,Camille Chua,Bryan Boubion,Kathryn Osann,Hans S. Keirstead +8 more
TL;DR: Whereas distant migration was not encountered in the liver or lung, 2 transplanted rats developed abnormal foci of growth, that is, tumors, from the external anal sphincter—raising further safety questions.
Patent
Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
TL;DR: In this article, the authors provided cancer stem cells, for use in stimulating immune response against a cancer, such as hepatocellular carcinoma (HCC), and methods for preparing and purifying the stem cells were provided.
Patent
Immunogenic compositions prepared from tumor cells derived from peripheral blood and originating from a solid tumor and their use
Gabriel Nistor,Hans S. Keirstead +1 more
TL;DR: In this paper, an immunopotent tumor-specific cancer cell product containing an immunogenic composition containing immunostimulatory amount of an isolated population of dendritic cells contacted ex vivo with a cancer- specific cancer stem cell derived from a tumor cell, a tumor cluster, tumor cell aggregate or a combination thereof expressing at least one cancer-specific antigen, the tumor cell or aggregate being derived from peripheral blood; and an adjuvant; and a pharmaceutically acceptable carrier.
Journal ArticleDOI
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment
Daniela A. Bota,Thomas H. Taylor,David Piccioni,Christopher Duma,Renato V. LaRocca,Santosh Kesari,Jose Carrillo,Mehrdad Abedi,Robert Aiken,Frank P.K. Hsu,Xiao-Tang Kong,Candace Hsieh,Peter G. Bota,Gabriel Nistor,Hans S. Keirstead,Robert O. Dillman +15 more
TL;DR: A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AVGBM1 administration, and (3) survival as mentioned in this paper .